Brain Trauma Imaging

¹Department of Nuclear Medicine, University of Cologne, Cologne, Germany;
²Institute for Neuroscience and Medicine II–Molecular Organization of the Brain, Research Center Juelich, Juelich, Germany; and
³Department of Radiology and Imaging Sciences, University of Utah, Salt Lake City, Utah
Learning Objectives: On successful completion of this activity, participants should be able to describe (1) the current status of brain imaging for the evaluation and diagnosis of brain injuries; (2) the advantages and disadvantages of different imaging modalities used for research of traumatic brain injury; and (3) specific radioligands that have been applied to characterize brain alterations in a chronic phase following injury.Financial Disclosure: Support was received from VA Rehabilitation Research and Development (grants I01RX000521, I01RX001612, and I01RX003087: Elaine R. Peskind, PI); the NIH (grant 5R01NS045254-05 to Satoshi Minoshima and Donna Cross); and, to Gérard Bischof, via Köln Fortune 479/2018 and Hannelore-Kohl Stiftung e.V. (grant 2018016). Gérard Bischof has been funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) via project 431549029–SFB 1451. Donna Cross is on the scientific advisory board for Ceremark Pharma, the producer of ¹⁸F-FDDNP (Flornaptitril). This tracer for CTE was not discussed in the article. The authors of this article have indicated no other relevant relationships that could be perceived as a real or apparent conflict of interest.CME Credit: SNMMI is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing education for physicians. SNMMI designates each JNM continuing education article for a maximum of 2.0 AMA PRA Category 1 Credits. Physicians should claim only credit commensurate with the extent of their participation in the activity. For CE credit, SAM, and other credit types, participants can access this activity through the SNMMI website (http://www.snmmilearningcenter.org) through January 2026.